Stem cells hold great promise as novel and encouraging therapeutic tools in the treatment
of degenerative disorders due to their differentiation potential while maintaining the capability
to self-renewal and their unlimited ability to divide and regenerate tissue. A variety of different
types of stem cells can be used in cell therapy. Among these, mesenchymal stem cell (MSC) therapy
has gradually established itself as a novel method for treating damaged tissues that need restoration
and renewal. Male infertility is an important health challenge affecting approximately
8-12% of people around the world. This abnormality can be caused by primary, congenital, acquired,
or idiopathic reasons. Men with no sperm in their semen have a condition called azoospermia,
caused by non-obstructive (NOA) causes and post-testicular obstructive causes. Accumulating
evidence has shown that various types of MSCs can differentiate into germ cells and improve
spermatogenesis in the seminiferous tubules of animal models. In addition, recent studies in animal
models have exhibited that extracellular vesicles derived from MSCs can stimulate the progression
of spermatogenesis and germ cell regeneration in the recipient testes. In spite of the fact
that various improvements have been made in the treatment of azoospermia disorder in animal
models by MSC or their extracellular vesicles, no clinical trials have been carried out to test their
therapeutic effect on the NOA. In this review, we summarize the potential of MSC transplantation
for treating infertility caused by NOA.